AMD-HALT programme receives Eurostars grant for continued investigation of dry AMD gene therapy platform

News
Article

Phenocell and Amarna Therapeutics were awarded the grant by Eureka’s Eurostars initiative, co-funded by the European Union

An image of the Euro symbol against a backdrop of digital imagery, including an LED-like screen and circuitry. Image credit: ©Who is Danny – stock.adobe.com

The Phenocell-Amarna AMD-HALT project was recognised for its potential to address “a critical gap in ophthalmology” and shining new light on retinal disease pathologies. Image credit: ©Who is Danny – stock.adobe.com

Two European companies received the competitive Eurostars grant to support a gene therapy platform for patients with dry age-related macular degeneration (AMD). Phenocell SAS (Axol Bioscience), a stem cell-derived model and service provider based in France, and Amarna Therapeutics, a gene therapy biotechnology firm based in the Netherlands, announced the award for their joint project AMD-HALT. According to a press release, the collaboration pairs Amarna’s SV40-derived gene delivery vector platform with Phenocell’s in vitro AMD disease model, which accurately mimics cellular interactions and microenvironment of the retina.1 The Eurostars programme is part of the European Partnership on Innovative Small and Medium Enterprises (SMEs), co-funded through the European Union through Horizon Europe.

The joint press release detailed the gene therapy venture, AMD-HALT. Phenocell aims to develop a three-dimensional in vitro cellular disease model for dry AMD, based on induced pluripotent stem cells (iPSC)-derived retinal pigment epithelium, microglial and photoreceptor cells. Using the patented recombinant vector developed by Amarna, Nimvec, which inhibits inflammation and promotes tissue regeneration. Investigators will assess the efficacy and mode-of-action of the Nimvec vector using the disease model. The companies called the programme a “first step in the development of an effective curative treatment for this high impact disease.”

Eurostars supports innovative, market-oriented research and development projects led by SMEs, and puts a particular emphasis on cross-border collaborations. The Phenocell-Amarna AMD-HALT project was recognised for its potential to address “a critical gap in ophthalmology,” and as a means of generating broader understanding of retinal disease. The companies jointly acknowledged the grant-writing and project development of support of Catalyze, credited with securing the Eurostars funding.

In a statement, Phenocell’s founder, R&D and site leader, Brigitte Onteniente, PhD, said, “Our iPSC-derived retinal cells and advanced co-culture methodologies offer unprecedented potential to create physiologically relevant disease models. This Eurostars grant is a testament to the transformative impact this project could have on the field.”

Henk Streefkerk, MD, PhD, CEO and medical director of Amarna, also praised the partnership. He said, “Partnering with Phenocell on this Eurostars-funded project is a critical step in advancing our proprietary gene therapy technology. The three-dimensional in vitro cellular disease models will enable us to evaluate the therapeutic potential of our gene therapy candidates with unprecedented accuracy, accelerating progress toward effective treatments for diseases such as dry AMD.”

Reference

1. Phenocell and Amarna Therapeutics Awarded Eurostars Grant to Assess a Gene Therapy for Dry AMD using a novel 3-dimensional iPSC-derived Retinal Model of the Disease. News release. Amarna Therapeutics. Published 11 December, 2024. Accessed 12 December, 2024. https://www.wjtv.com/business/press-releases/globenewswire/1001028116/phenocell-and-amarna-therapeutics-awarded-eurostars-grant-to-assess-a-gene-therapy-for-dry-amd-using-a-novel-3-dimensional-ipsc-derived-retinal-model-of-the-disease/

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.